No Correlation Between Urate Crystal Identification and Cardiovascular Risk

A Danish cohort study examined patients with hyperuricemia and compared outcomes in those proven to have urate crystal deposition (317 patients) and matched 1:1 to patients without urate crystals. Interestingly, of the 80,726, 79,629 did not have uric acid crystal identification.

They found no difference between the two groups with regard to cardiovascular outcomes (hazard ratios = 0.86; 95 % confidence interval (CI) 0.52 - 1.43) or death (hazard ratio 0.74; CI 0.45 - 1.21). Hence, the presence of urate crystal precipitations does not to confer an added cardiovascular risk in hyperuricemic patients.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Modifiable Risk Factors for Hyperuricemia

By Jack Cush, MD | 05 Sep 2019

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia.

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

[...]

Opioids Overused in Acute Gout

By MedPage Today | 08 Jul 2019

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

[...]

Allopurinol Fails to Curtail Hypertension

By Jack Cush, MD | 03 Jul 2019

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

[...]

Allopurinol Fails to Curtail Hypertension

By Jack Cush, MD | 19 Jun 2019

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

[...]

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

By Jack Cush, MD | 10 Jun 2019

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

[...]

You are here